相关实验视频
Updated: Feb 26, 2026

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
18.5K
突出了儿童艾滋病毒临床管理方面的进展
Rebecka Papaioannu Borjesson1, Tommaso Clemente1, Antonella Castagna1,2
1Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Expert opinion on pharmacotherapy
|February 25, 2026
概括
儿科HIV需要更早的诊断和优化的抗逆转录病毒疗法 (ART) 以更好地抑制病毒. 关键的优先事项包括儿童友好的饮食方案,耐药性测试和管理相关疾病,以改善长期健康结果.
科学领域:
- 儿童传染病 儿童传染病
- 艾滋病毒/艾滋病管理
- 抗逆转录病毒疗法研究研究
背景情况:
- 儿科艾滋病毒影响全球140万儿童,诊断和治疗方面存在重大差距.
- 许多接受抗逆转录病毒治疗 (ART) 的儿童仍然没有病毒抑制,冒着疾病进展和耐药性的风险.
- 指导方针越来越多地建议儿童快速启动ART和基于整合酶抑制剂 (INSTI) 的治疗方案.
研究的目的:
- 审查当前关于ART启动,治疗方案选择和儿科HIV耐药性的证据.
- 检查主要的并发症及其与儿童和青少年终身ART的相互作用.
- 讨论护理的实际方面,并概述儿童艾滋病毒管理的未来治疗药物.
主要方法:
- 关于儿科艾滋病毒治疗现有证据的综合文献综述.
- 分析有关ART有效性,耐药性模式和并发症的数据.
- 探索儿童艾滋病毒治疗的新兴和管道中的药物.
主要成果:
- 优化ART治疗方案和早期诊断对于实现儿童病毒抑制至关重要.
- 营养不良和神经认知障碍等并发症显著影响终身ART管理.
- 抗逆转录病毒耐药性仍然是儿童艾滋病毒治疗的一个重大挑战.
结论:
- 儿童艾滋病毒的持久病毒抑制需要早期诊断,儿童友好的ART,耐药性测试和综合性并发症管理.
- 未来的研究应该集中在新型药物,改进的监测标志物和公平获得护理.
- 解决全球不平等问题对于有效管理儿科艾滋病毒至关重要.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
332
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
332
Retrovirus Life Cycles
50.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K
Cystic Fibrosis: Management
580
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
580
Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
Sexually Transmitted Infections
1.3K
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.3K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
377
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
377

